Premium
The Secretory Profile of Inflammatory Mediators is Altered in Differentiated Primary COPD Samples at Air Liquid Interface Compared to Healthy Equivalents
Author(s) -
Kelly Gillian A.,
Douglas Lisa E.J.,
Maye Jessica R.,
Reihill James A.,
McGarvey Lorcan P.,
Lundy Fionnuala T.,
Litherland Gary,
Martin S. Lorraine
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.127.8
Subject(s) - copd , proteases , protease , secretion , medicine , inflammation , population , pulmonary disease , immunology , pathology , biology , biochemistry , enzyme , environmental health
In the UK, over 1 million people live with diagnosed chronic obstructive pulmonary disease (COPD) however, it is estimated that this is only 1/3 of the total COPD population. Diagnosis is based on patient airflow obstruction, a late developing symptom, by which time a significant amount of lung damage has already occurred (1). Investigation into a range of biomarkers to aid earlier identification of COPD is therefore essential. Apical and basolateral samples collected from differentiated primary healthy and COPD cells at air liquid interface (ALI) were screened for 35 proteases, 32 protease inhibitors and 37 other inflammatory mediators using R&D Systems Proteome Profiler Protease array and Anti‐Protease array and BioRad Bio‐Plex Pro Human Inflammation Panel 1, 37‐Plex Assay respectively, with the aim of identifying potential biomarkers. Both apical and basolateral secretory profiles were altered in COPD samples compared to their healthy counterparts. The majority of apically secreted proteases were up‐regulated whereas, protease inhibitors were down‐regulated. Basolateral secretion of inflammatory mediators was found to be both up‐ and down‐regulated depending on which mediator was being measured. These initial results highlight interesting targets which will be further investigated in clinical samples to assess their potential as biomarkers to aid the earlier diagnosis of COPD. Support or Funding Information BREATH (Border and REgions Airways Training Hub) is funded by the EU's INTERREG Va programme managed by the Special EU Programmes Body (SEUPB) . This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .